Myelodysplastic syndromes are a group of cancers in which immature blood cells in the bone marrow do not mature or become healthy blood cells. There is no cure, but some medications can help slow the progression of the disease. Transfusions and medication helps manage the symptoms of the condition. Moreover, an allogeneic bone marrow transplant (BMT) is the only potential cure for patients with Myelodysplastic syndrome (MDS).
*The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/775
Increasing demand for Myelodysplastic syndrome treatment and introduction of novel drugs is expected to augment the growth of the global Myelodysplastic syndrome treatment market. For instance, in October 2016, Opsona Therapeutics announced that it has received an orphan drug designation (ODD) from U.S. Food and Drug Administration (FDA) for MDS. Moreover, in March 2017, FibroGen Inc. received FDA (China) approval to conduct Phase 2/3 trial of drug roxadustat in low risk MDS patients with anemia.
Furthermore, market players are adopting inorganic growth strategies such as partnership and collaboration, which in turn is expected to boost the growth of the Myelodysplastic syndrome treatment market. For instance, in October 2016, Dr. Reddy’s Laboratories and Gland Pharma teamed up to market and distribute diverse portfolio of eight injectable abbreviated new drug applications (ANDAs) in the US market.
North America is expected to witness robust growth in the global Myelodysplastic syndrome treatment market due to the Increasing demand for MDS treatment and frequent approval and launched of novel drugs in the region. For instance, in November 2017, Cipla received FDA approval for its new drug route of administration for Decitabine injection, a generic version of Otsuka America Pharmaceutical Inc.’s Dacogen.
Key players operating in the global Myelodysplastic syndrome treatment market are Geron, FibroGen Inc., Aprea Therapeutics, Acceleron Pharma, Inc., Cipla Limited, Mylan NV, Teva Pharmaceutical Industries Ltd., Celgene Corporation, Otsuka Pharmaceutical Co., Onconova Therapeutics Inc., and Sun Pharmaceutical Industries Limited, among others.
In December 2018, Celgene Corporation and Acceleron Pharma Inc. announced results from the pivotal, phase 3 MEDALIST trial evaluating the efficacy and safety of luspatercept to treat patients with ring sideroblast (RS+) MDS-associated anemia.
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy This Report with Flat USD 2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/775
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Myelodysplastic Syndrome (MDS) Treatment Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Myelodysplastic Syndrome (MDS) Treatment Industry Impact
Chapter 2 Global Myelodysplastic Syndrome (MDS) Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Myelodysplastic Syndrome (MDS) Treatment (Volume and Value) by Type
2.3 Global Myelodysplastic Syndrome (MDS) Treatment (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Myelodysplastic Syndrome (MDS) Treatment Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Myelodysplastic Syndrome (MDS) Treatment Market Analysis
Chapter 6 East Asia Myelodysplastic Syndrome (MDS) Treatment Market Analysis
Chapter 7 Europe Myelodysplastic Syndrome (MDS) Treatment Market Analysis
Chapter 8 South Asia Myelodysplastic Syndrome (MDS) Treatment Market Analysis
Chapter 9 Southeast Asia Myelodysplastic Syndrome (MDS) Treatment Market Analysis
Chapter 10 Middle East Myelodysplastic Syndrome (MDS) Treatment Market Analysis
Chapter 11 Africa Myelodysplastic Syndrome (MDS) Treatment Market Analysis
Chapter 12 Oceania Myelodysplastic Syndrome (MDS) Treatment Market Analysis
Chapter 13 South America Myelodysplastic Syndrome (MDS) Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Myelodysplastic Syndrome (MDS) Treatment Business
Chapter 15 Global Myelodysplastic Syndrome (MDS) Treatment Market Forecast (2021-2027)
Chapter 16 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027